TD Cowen Reiterates Buy Rating on Revolution Medicines, Inc. (RVMD)

Market Context

Revolution Medicines, Inc. operates in the Healthcare sector. The stock currently trades at $177.65 with a market capitalization of $15.2B. The stock has gained 227.3% over the past 52 weeks.

Analyst coverage from TD Cowen provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Revolution Medicines, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Revolution Medicines, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 05, 2026	TD Cowen	Buy	N/A
Nov 05, 2026	Guggenheim	Buy	N/A
Nov 05, 2026	Truist Securities	Buy	N/A
Nov 05, 2026	Piper Sandler	Overweight	N/A
Nov 05, 2026	RBC Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View RVMD Stock Page